Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Caron Alyce Jacobson, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023 Jan 01; 108(1):98-109. PMID: 35833303; PMCID: PMC9827150.
    Citations:    Fields:    
  2. Cliff ERS, Merryman RW, Armand P, Jacobson CA. Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma. Nat Med. 2022 12; 28(12):2458-2459. PMID: 36348063.
    Citations:    Fields:    Translation:HumansCells
  3. Jones DK, Eckhardt CA, Sun H, Tesh RA, Malik P, Quadri S, Firme MS, van Sleuwen M, Jain A, Fan Z, Jing J, Ge W, Nascimento FA, Sheikh IS, Jacobson C, Frigault M, Kimchi EY, Cash SS, Lee JW, Dietrich J, Westover MB. EEG-based grading of immune effector cell-associated neurotoxicity syndrome. Sci Rep. 2022 11 21; 12(1):20011. PMID: 36414694; PMCID: PMC9681864.
    Citations:    Fields:    Translation:Humans
  4. Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, Freedman AS, Jacobsen ED, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Jacene H, Park H, Dahi PB, Nieto Y, Joyce R, Chen YB, Shipp MA, Herrera AF, Armand P. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2022 Nov 18. PMID: 36399518.
    Citations:    Fields:    
  5. Amidi Y, Eckhardt CA, Quadri SA, Malik P, Firme MS, Jones DK, Jain A, Danish HH, Rubin DB, Jacobson CA, Cash SS, Lee JW, Dietrich J, Westover MB. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy. J Immunother Cancer. 2022 11; 10(11). PMID: 36450377; PMCID: PMC9716920.
    Citations:    Fields:    Translation:Humans
  6. Miller KC, Johnson PC, Abramson JS, Soumerai JD, Yee AJ, Branagan AR, O'Donnell EK, Saucier A, Jacobson CA, Frigault MJ, Raje NS. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J. 2022 11 01; 12(10):146. PMID: 36316312; PMCID: PMC9622902.
    Citations:    Fields:    Translation:Humans
  7. Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, Gallagher KME, Katsis K, Frigault MJ, Southard J, Li S, Kann MC, Silva H, Jan M, Rhrissorrakrai K, Utro F, Levovitz C, Jacobs RA, Slowik K, Danysh BP, Livak KJ, Parida L, Ferry J, Jacobson C, Wu CJ, Getz G, Maus MV. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022 09; 28(9):1848-1859. PMID: 36097221; PMCID: PMC9509487.
    Citations: 1     Fields:    Translation:HumansCells
  8. Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, Chang EC, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ, Lin Y, Ghobadi A, Kim JJ, Chou J, Plaks V, Wang Z, Xue A, Mattie M, Rossi JM, Bot A, Galon J. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022 09; 28(9):1872-1882. PMID: 36038629; PMCID: PMC9499856.
    Citations: 5     Fields:    Translation:Humans
  9. Ghione P, Palomba ML, Patel AR, Bobillo S, Deighton K, Jacobson CA, Nahas M, Hatswell AJ, Jung AS, Kanters S, Snider JT, Neelapu SS, Ribeiro MT, Brookhart MA, Ghesquieres H, Radford J, Gribben JG. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 2022 08 25; 140(8):851-860. PMID: 35679476; PMCID: PMC9412012.
    Citations: 1     Fields:    
  10. Little JS, Aleissa MM, Beluch K, Gonzalez-Bocco IH, Marty FM, Manne-Goehler J, Koo S, Hammond SP, Jacobson CA. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Adv. 2022 08 23; 6(16):4821-4830. PMID: 35802461; PMCID: PMC9631654.
    Citations:    Fields:    
  11. Jacobsen ED, Kim HT, Jeter E, Jacobson C, Fisher DC, Armand P. Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma. Bone Marrow Transplant. 2022 11; 57(11):1719-1720. PMID: 35996021.
    Citations:    Fields:    Translation:HumansCells
  12. Taranto E, Redd R, Jeter E, McHugh K, Crombie JL, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Odejide OO, Dahi PB, Nieto Y, Joyce RM, Chen YB, Bonjoc KC, Chaudhry A, Herrera AF, Armand P, Merryman RW. Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma. 2022 12; 63(12):2912-2917. PMID: 35938581.
    Citations:    Fields:    Translation:HumansCells
  13. Darnell EP, Jacobson CA. German CARs keeping pace. Blood. 2022 07 28; 140(4):296-298. PMID: 35900785.
    Citations:    Fields:    
  14. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. 2023 Jan 20; 41(3):555-567. PMID: 35658525; PMCID: PMC9870225.
    Citations:    Fields:    
  15. Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, Ahmed S, Ghobadi A, Miklos DB, Lin Y, Perales MA, Lunning MA, Herr MM, Hill BT, Ganguly S, Dong H, Nikiforow S, Hooper M, Kawashima J, Xu H, Pasquini MC. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. Transplant Cell Ther. 2022 09; 28(9):581.e1-581.e8. PMID: 35609867; PMCID: PMC9427701.
    Citations:    Fields:    
  16. Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2022 May; 9(5):e374-e384. PMID: 35483398; PMCID: PMC9241484.
    Citations:    Fields:    Translation:Humans
  17. Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, Lehmberg TZ, Parry EM, Wu CJ, Jacobson CA, Fisher DC, Thompson PA, Brown JR. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022 02 03; 139(5):686-689. PMID: 34788401; PMCID: PMC8814674.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  18. Holroyd KB, Rubin DB, LaRose S, Monk A, Nikiforow S, Jacobson C, Vaitkevicius H. Use of Transcranial Doppler as a Biomarker of CAR T Cell-Related Neurotoxicity. Neurol Clin Pract. 2022 Feb; 12(1):22-28. PMID: 36157627; PMCID: PMC9491503.
    Citations:    
  19. Beuchat I, Danish HH, Rubin DB, Jacobson C, Robertson M, Vaitkevicius H, Lee JW. EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations. Neuro Oncol. 2022 02 01; 24(2):313-325. PMID: 34265061; PMCID: PMC8804895.
    Citations: 1     Fields:    Translation:HumansCells
  20. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 02 17; 386(7):640-654. PMID: 34891224.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  21. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022 01; 23(1):91-103. PMID: 34895487.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  22. Aghajan Y, Yu A, Jacobson CA, Kim AI, Kean L, Robertson M, Vaitkevicius H. Myelopathy Because of CAR-T-Related Neurotoxicity Treated With Siltuximab. Neurol Clin Pract. 2021 Dec; 11(6):e944-e946. PMID: 34992991; PMCID: PMC8723956.
    Citations: 1     
  23. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste E, Farooq U, Navale L, DePuy V, Kim JJ, Gisselbrecht C. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021 10 26; 5(20):4149-4155. PMID: 34478487; PMCID: PMC8945634.
    Citations: 5     Fields:    Translation:HumansCells
  24. Merryman RW, Redd R, Jeter E, Wong JL, McHugh K, Reynolds C, Nazzaro M, Varden A, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Dahi PB, Nieto Y, Joyce RM, Chen YB, Herrera AF, Armand P, Ritz J. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplant Cell Ther. 2022 01; 28(1):32.e1-32.e10. PMID: 34670169; PMCID: PMC8792205.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  25. Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman M, DeFilipp Z, Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Jaglowski S, Lachance S, Langston A, Mattar B, Maziarz RT, McGuirk J, Mian MAH, Nathan S, Phillips A, Rakszawski K, Sengeloev H, Shenoy S, Stuart R, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv. 2021 09 28; 5(18):3528-3539. PMID: 34496026; PMCID: PMC8945575.
    Citations: 2     Fields:    Translation:Humans
  26. Crombie JL, Nastoupil LJ, Redd R, Tang K, Shouse G, Herrera AF, Chow VA, Shadman M, Castaneda Puglianini O, Saucier A, Jacobson CA, Armand P, Simmons G. Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. Blood Adv. 2021 09 28; 5(18):3563-3567. PMID: 34474474; PMCID: PMC8945592.
    Citations:    Fields:    Translation:Humans
  27. Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, Wang Z, Kuang SQ, Chu F, Davis RE, Vega F, Bashir Z, Jacobson CA, Locke FL, Reagan PM, Rodig SJ, Lekakis LJ, Flinn IW, Miklos DB, Bot A, Neelapu SS. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood. 2021 09 23; 138(12):1081-1085. PMID: 34041526.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  28. Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, Montegaard J, Patterson V, Weinstock M, Crombie JL, Ng SY, Kim AI, Jacobson CA, LaCasce AS, Armand P, Arnason JE, Fisher DC, Brown JR. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021 10; 22(10):1391-1402. PMID: 34534514.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  29. Miller PG, Sperling AS, Brea EJ, Leick MB, Fell GG, Jan M, Gohil SH, Tai YT, Munshi NC, Wu CJ, Neuberg DS, Maus MV, Jacobson C, Gibson CJ, Ebert BL. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021 08 10; 5(15):2982-2986. PMID: 34342642; PMCID: PMC8361461.
    Citations: 4     Fields:    Translation:Humans
  30. Westin J, Maris MB, Jacobson CA, Patel P, Lakhani N, Harb W, Patel-Donnelly D, McCaul K, Escobar C, Klencke B, Al-Katib AM. Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 01; 22(1):52-59. PMID: 34454850.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  31. Oluwole OO, Bouabdallah K, Muñoz J, De Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney PA, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Kim JJ, Bashir Z, McLeroy J, Zheng Y, Rossi JM, Johnson L, Goyal L, van Meerten T. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021 08; 194(4):690-700. PMID: 34296427.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  32. Rubin DB, Jacobson C, Vaitkevicius H. Risk Factors With Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy-Reply. JAMA Neurol. 2021 06 01; 78(6):764-765. PMID: 33900372.
    Citations:    Fields:    Translation:Humans
  33. Johnson PC, Jacobson C, Yi A, Saucier A, Dhawale TM, Nelson A, Lavoie MW, Reynolds MJ, Topping CEW, Frigault MJ, El-Jawahri A. Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy. J Natl Compr Canc Netw. 2021 03 11; 19(8):928-934. PMID: 33706257.
    Citations:    Fields:    Translation:Humans
  34. Griffin GK, Weirather JL, Roemer MGM, Lipschitz M, Kelley A, Chen PH, Gusenleitner D, Jeter E, Pak C, Gjini E, Chapuy B, Rosenthal MH, Xu J, Chen BJ, Sohani AR, Lovitch SB, Abramson JS, Ishizuka JJ, Kim AI, Jacobson CA, LaCasce AS, Fletcher CD, Neuberg D, Freeman GJ, Hodi FS, Wright K, Ligon AH, Jacobsen ED, Armand P, Shipp MA, Rodig SJ. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 03 11; 137(10):1353-1364. PMID: 32871584; PMCID: PMC8555417.
    Citations: 7     Fields:    Translation:HumansCells
  35. Jacobson CA. Highlights in CAR T-cell therapy from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. Clin Adv Hematol Oncol. 2021 Mar; 19 Suppl 10(3):19-23. PMID: 33843918.
    Citations:    Fields:    Translation:Humans
  36. Newcomb R, Jacobson C. Chimeric Antigen Receptor T Cells for B-Cell Lymphoma. Cancer J. 2021 Mar-Apr 01; 27(2):107-111. PMID: 33750069.
    Citations:    Fields:    Translation:HumansCells
  37. Maurer K, Saucier A, Kim HT, Acharya U, Mo CC, Porter J, Albert C, Cutler C, Antin JH, Koreth J, Gooptu M, Romee R, Wu CJ, Soiffer RJ, Nikiforow S, Jacobson C, Ho VT. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 02 09; 5(3):861-871. PMID: 33560397; PMCID: PMC7869610.
    Citations: 5     Fields:    Translation:HumansCells
  38. Smith SD, Lopedote P, Samara Y, Mei M, Herrera AF, Winter AM, Hill BT, Shadman M, Ujjani C, Lynch RC, Jacobson CA, Kim AI, Caimi P, Milano F, Gopal AK. Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):170-175. PMID: 33431309.
    Citations: 3     Fields:    Translation:Humans
  39. Shapiro GI, LoRusso P, Dowlati A, T Do K, Jacobson CA, Vaishampayan U, Weise A, Caimi PF, Eder JP, French CA, Labriola-Tompkins E, Boisserie F, Pierceall WE, Zhi J, Passe S, DeMario M, Kornacker M, Armand P. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021 02; 124(4):744-753. PMID: 33311588; PMCID: PMC7884382.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  40. Rubin DB, Al Jarrah A, Li K, LaRose S, Monk AD, Ali AB, Spendley LN, Nikiforow S, Jacobson C, Vaitkevicius H. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. JAMA Neurol. 2020 12 01; 77(12):1536-1542. PMID: 32777012.
    Citations: 13     Fields:    Translation:Humans
  41. Chase ML, Merryman R, Fisher DC, Jacobsen E, LaCasce A, Jacobson C, Freedman A, Davids MS, Brown JR, Jacob A, Armand P, Crombie J. A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leuk Lymphoma. 2021 02; 62(2):478-481. PMID: 33236969.
    Citations:    Fields:    Translation:Humans
  42. Jacobson CA, Maus MV. C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. Blood Adv. 2020 11 24; 4(22):5858-5862. PMID: 33232481.
    Citations: 3     Fields:    Translation:HumansCells
  43. Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, Spendley L, Nikiforow S, Jacobson C, Nohria A. Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma. Circulation. 2020 10 27; 142(17):1687-1690. PMID: 33104402.
    Citations: 15     Fields:    Translation:Humans
  44. Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, Lin Y, Sherman M, Better M, Go WY, Wiezorek JS, Xue A, Bot A. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 10 13; 4(19):4898-4911. PMID: 33035333; PMCID: PMC7556133.
    Citations: 43     Fields:    Translation:Humans
  45. Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 09 20; 38(27):3095-3106. PMID: 32667831; PMCID: PMC7499617.
    Citations: 49     Fields:    Translation:HumansCells
  46. Chen PH, Lipschitz M, Weirather JL, Jacobson C, Armand P, Wright K, Hodi FS, Roberts ZJ, Sievers SA, Rossi J, Bot A, Go W, Rodig SJ. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight. 2020 06 18; 5(12). PMID: 32484797; PMCID: PMC7406247.
    Citations: 15     Fields:    Translation:HumansCells
  47. Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Locke FL. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020 06 04; 135(23):2106-2109. PMID: 32181801; PMCID: PMC7273828.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  48. Merryman RW, Houot R, Armand P, Jacobson C. Immune and Cell Therapy in Non-Hodgkin Lymphoma. Cancer J. 2020 May/Jun; 26(3):269-277. PMID: 32496460.
    Citations: 1     Fields:    Translation:Humans
  49. Houot R, Armand P, Jacobson CA. Chimeric antigen receptor (CAR) T-cells on the march: from diffuse large B-cell lymphoma to mantle cell lymphoma. Eur J Cancer. 2020 05; 131:51-52. PMID: 32283478.
    Citations:    Fields:    Translation:HumansCells
  50. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020 04 02; 382(14):1331-1342. PMID: 32242358; PMCID: PMC7731441.
    Citations: 286     Fields:    Translation:HumansCellsCTClinical Trials
  51. Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867. PMID: 32126141; PMCID: PMC7065472.
    Citations: 10     Fields:    Translation:Humans
  52. Gopal AK, Levy R, Houot R, Patel SP, Popplewell L, Jacobson C, Mu XJ, Deng S, Ching KA, Chen Y, Davis CB, Huang B, Fly KD, Thall A, Woolfson A, Bartlett NL. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 06 01; 26(11):2524-2534. PMID: 32144134.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  53. Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020 05; 95(5):510-520. PMID: 32052473; PMCID: PMC7383599.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  54. Jacobson CA. Highlights in CAR T-cell therapy from the 61st American Society of Hematology Annual Meeting: commentary. Clin Adv Hematol Oncol. 2020 Feb; 18 Suppl 7(2):20-23. PMID: 33843872.
    Citations:    Fields:    Translation:Humans
  55. Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O'Donnell EK, Jacobson CA, Motwani SS, Parikh SM, Curhan GC, Reynolds KL, Leaf DE, Sise ME. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Am J Kidney Dis. 2020 07; 76(1):63-71. PMID: 31973908.
    Citations: 20     Fields:    Translation:Humans
  56. Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Bsat J, Patel SS, Ritz J, Rodig SJ, Shipp MA, Chen YB, Joyce RM. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126. PMID: 31917843; PMCID: PMC6960482.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  57. Jacobson CA. Indolent lymphomas: pushing the pace with novel agents. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):279-286. PMID: 31808854.
    Citations:    Fields:    Translation:Humans
  58. Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, Montegaard J, Patterson V, Jacobson CA, Jacobsen ED, LaCasce AS, Arnason JE, Armand P, Fisher DC, Brown JR, Davids MS. Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32. PMID: 31723987.
    Citations:    
  59. Jacobson CA, Farooq U, Ghobadi A. Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist. Oncologist. 2020 01; 25(1):e138-e146. PMID: 31585984; PMCID: PMC6964143.
    Citations: 9     Fields:    Translation:Humans
  60. Jacobson C, Emmert A, Rosenthal MB. CAR T-Cell Therapy: A Microcosm for the Challenges Ahead in Medicare. JAMA. 2019 Sep 10; 322(10):923-924. PMID: 31355862.
    Citations: 5     Fields:    
  61. Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 12; 25(12):2305-2321. PMID: 31446199.
    Citations: 39     Fields:    
  62. Hunter BD, Rogalski M, Jacobson CA. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. Expert Opin Biol Ther. 2019 11; 19(11):1157-1164. PMID: 31342797.
    Citations: 3     Fields:    Translation:HumansCells
  63. Hunter BD, Jacobson CA. CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions. J Natl Cancer Inst. 2019 07 01; 111(7):646-654. PMID: 30753567.
    Citations: 49     Fields:    Translation:HumansCells
  64. Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug; 6(8):e419-e428. PMID: 31208944; PMCID: PMC7036668.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  65. Jacobson CA. Redefining Non-Hodgkin Lymphoma: Using Genomic Subtypes to Improve Treatment Options. Hematol Oncol Clin North Am. 2019 08; 33(4):xiii-xiv. PMID: 31229166.
    Citations:    Fields:    Translation:HumansCells
  66. Hunter BD, Chen YB, Jacobson CA. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma. Hematol Oncol Clin North Am. 2019 08; 33(4):687-705. PMID: 31229163.
    Citations: 4     Fields:    Translation:Humans
  67. Rubin DB, Danish HH, Ali AB, Li K, LaRose S, Monk AD, Cote DJ, Spendley L, Kim AH, Robertson MS, Torre M, Smith TR, Izzy S, Jacobson CA, Lee JW, Vaitkevicius H. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019 05 01; 142(5):1334-1348. PMID: 30891590.
    Citations: 48     Fields:    Translation:Humans
  68. Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174. PMID: 30967392.
    Citations: 10     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  69. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29. PMID: 30952672; PMCID: PMC6609955.
    Citations: 42     Fields:    Translation:HumansCTClinical Trials
  70. Acharya UH, Dhawale T, Yun S, Jacobson CA, Chavez JC, Ramos JD, Appelbaum J, Maloney DG. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol. 2019 03; 12(3):195-205. PMID: 30793644.
    Citations: 27     Fields:    Translation:HumansAnimals
  71. Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 2019 Jan; 6(1):e38-e47. PMID: 30558987; PMCID: PMC7132223.
    Citations: 38     Fields:    Translation:HumansCTClinical Trials
  72. Jacobson CA. CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma. J Clin Oncol. 2019 02 01; 37(4):328-335. PMID: 30557517.
    Citations: 13     Fields:    Translation:Humans
  73. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 01; 20(1):31-42. PMID: 30518502; PMCID: PMC6733402.
    Citations: 506     Fields:    Translation:HumansCTClinical Trials
  74. Jacobson CA, Armand P. Immunotherapy in aggressive B-cell lymphomas. Best Pract Res Clin Haematol. 2018 09; 31(3):299-305. PMID: 30213400.
    Citations: 2     Fields:    Translation:Humans
  75. Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018 Nov; 5(11):e563-e598. PMID: 29907552; PMCID: PMC6261436.
    Citations: 32     Fields:    Translation:Humans
  76. Sun L, Li S, El-Jawahri A, Armand P, Dey BR, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, McAfee SL, Spitzer TR, Chen YB, DeFilipp Z. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis. Oncologist. 2018 05; 23(5):624-630. PMID: 29284757.
    Citations: 9     Fields:    Translation:Humans
  77. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 12 28; 377(26):2531-2544. PMID: 29226797; PMCID: PMC5882485.
    Citations: 1363     Fields:    Translation:HumansCellsCTClinical Trials
  78. Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31. PMID: 28034071; PMCID: PMC5455688.
    Citations: 56     Fields:    Translation:Humans
  79. Jacobson C, Kopp N, Layer JV, Redd RA, Tschuri S, Haebe S, van Bodegom D, Bird L, Christie AL, Christodoulou A, Saur A, Tivey T, Zapf S, Bararia D, Zimber-Strobl U, Rodig SJ, Weigert O, Weinstock DM. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood. 2016 11 24; 128(21):2517-2526. PMID: 27742706.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  80. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. PMID: 27479034.
    Citations: 26     Fields:    
  81. Jacobson CA, Freedman AS. Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma. Curr Hematol Malig Rep. 2016 06; 11(3):218-23. PMID: 26995595.
    Citations:    Fields:    Translation:Humans
  82. Mason EF, Brown RD, Szeto DP, Gibson CJ, Jia Y, Garcia EP, Jacobson CA, Dal Cin P, Kuo FC, Pinkus GS, Lindeman NI, Sholl LM, Aster JC, Morgan EA. Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. Leuk Lymphoma. 2017 01; 58(1):233-236. PMID: 27241017.
    Citations: 17     Fields:    Translation:Humans
  83. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203. PMID: 27247136; PMCID: PMC4946200.
    Citations: 120     Fields:    Translation:HumansCTClinical Trials
  84. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. PMID: 27070704; PMCID: PMC5177991.
    Citations: 114     Fields:    Translation:HumansAnimalsCells
  85. Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, LaCasce AS, Jacobson C, Davids MS, Brown JR, Weng L, Wilkins J, Faham M, Freedman AS, Joyce R, Jacobsen ED. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016 Apr; 173(1):89-95. PMID: 26729345.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  86. Jacobson CA, Freedman AS. Rethinking Prognosis and Therapy for Follicular Lymphoma. J Clin Oncol. 2015 Aug 10; 33(23):2489-91. PMID: 26169620.
    Citations:    Fields:    Translation:Humans
  87. Jacobson CA, Freedman AS. Is observation dead in follicular lymphoma? Still appropriate. J Natl Compr Canc Netw. 2015 Mar; 13(3):367-70. PMID: 25736012.
    Citations: 4     Fields:    Translation:Humans
  88. Jacobson C, LaCasce A. How I treat Burkitt lymphoma in adults. Blood. 2014 Nov 06; 124(19):2913-20. PMID: 25258344.
    Citations: 31     Fields:    Translation:Humans
  89. Jacobson CA, Sun L, Kim HT, McDonough SM, Reynolds CG, Schowalter M, Koreth J, Cutler CS, Ho VT, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Ritz J, Sarantopoulos S. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 May; 20(5):668-75. PMID: 24462743.
    Citations: 22     Fields:    Translation:HumansCells
  90. Jacobson CA, Freedman AS. One size does not fit all in follicular lymphoma. J Clin Oncol. 2013 Sep 20; 31(27):3307-8. PMID: 23960176.
    Citations: 1     Fields:    Translation:Humans
  91. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6. PMID: 23795711.
    Citations: 36     Fields:    Translation:HumansCells
  92. Jacobson CA, Freedman AS. First-line treatment of indolent lymphoma: axing CHOP? Lancet. 2013 Apr 06; 381(9873):1163-5. PMID: 23433738.
    Citations: 3     Fields:    Translation:Humans
  93. Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013 Mar; 160(5):608-17. PMID: 23278720.
    Citations: 22     Fields:    Translation:Humans
  94. Jacobson CA, Freedman AS. Early stage follicular lymphoma, current management and controversies. Curr Opin Oncol. 2012 Sep; 24(5):475-9. PMID: 22820411.
    Citations: 3     Fields:    Translation:Humans
  95. Jacobson CA, Abramson JS. HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART. Adv Hematol. 2012; 2012:507257. PMID: 22272202.
    Citations: 18     
  96. Jacobson CA, Longo DL. Follicular lymphoma: to treat or not to treat is no longer the question. J Natl Cancer Inst. 2012 Jan 04; 104(1):3-5. PMID: 22190632.
    Citations:    Fields:    Translation:Humans
  97. Jacobson CA, Ritz J. Time to put the CAR-T before the horse. Blood. 2011 Nov 03; 118(18):4761-2. PMID: 22053170.
    Citations: 1     Fields:    Translation:HumansCells
  98. Jacobson CA, Turki AT, McDonough SM, Stevenson KE, Kim HT, Kao G, Herrera MI, Reynolds CG, Alyea EP, Ho VT, Koreth J, Armand P, Chen YB, Ballen K, Soiffer RJ, Antin JH, Cutler CS, Ritz J. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):565-74. PMID: 21875503.
    Citations: 75     Fields:    Translation:HumansCells
  99. Jacobson CA, Ritz J. B-cell-directed therapy for chronic graft-versus-host disease. Haematologica. 2010 Nov; 95(11):1811-3. PMID: 21037328.
    Citations: 4     Fields:    Translation:HumansCells
  100. Jacobson CA, LaCasce AS. Lymphoma: risk and response after solid organ transplant. Oncology (Williston Park). 2010 Sep; 24(10):936-44. PMID: 21138175.
    Citations: 10     Fields:    Translation:Humans
  101. Nichols GL, Jacobson CA, Ferman D, Lichtman SM. Unusual uterine recurrence of primary central nervous system lymphoma. Clin Adv Hematol Oncol. 2006 Sep; 4(9):697-8, discussion 699-700. PMID: 17099627.
    Citations:    Fields:    Translation:Humans
  102. Tiersten A, Wo J, Jacobson C, Weitzman A, Horwich T, Hesdorffer C, Savage D, Troxel A. Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer. Breast. 2004 Aug; 13(4):341-6. PMID: 15325671.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  103. Jacobson CA, Talbot SM, Vahdat LT, Troxel AB, Shriberg L, Brafman LB, Tiersten AD. Recreational exercise and quality of life among women undergoing adjuvant chemotherapy for breast cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):8195. PMID: 28015438.
    Citations:    
  104. Posern G, Zheng J, Knudsen BS, Kardinal C, Müller KB, Voss J, Shishido T, Cowburn D, Cheng G, Wang B, Kruh GD, Burrell SK, Jacobson CA, Lenz DM, Zamborelli TJ, Adermann K, Hanafusa H, Feller SM. Development of highly selective SH3 binding peptides for Crk and CRKL which disrupt Crk-complexes with DOCK180, SoS and C3G. Oncogene. 1998 Apr 16; 16(15):1903-12. PMID: 9591773.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  105. Montanaro F, Gee SH, Jacobson C, Lindenbaum MH, Froehner SC, Carbonetto S. Laminin and alpha-dystroglycan mediate acetylcholine receptor aggregation via a MuSK-independent pathway. J Neurosci. 1998 Feb 15; 18(4):1250-60. PMID: 9454835; PMCID: PMC6792747.
    Citations: 30     Fields:    Translation:AnimalsCells
  106. Rothschild M, Jacobson C, Vaske D, Tuggle C, Wang L, Short T, Eckardt G, Sasaki S, Vincent A, McLaren D, Southwood O, van der Steen H, Mileham A, Plastow G. The estrogen receptor locus is associated with a major gene influencing litter size in pigs. Proc Natl Acad Sci U S A. 1996 Jan 09; 93(1):201-5. PMID: 8552604; PMCID: PMC40206.
    Citations: 55     Fields:    Translation:Animals
  107. Hogge DE, McConnell M, Jacobson C, Sutherland HJ, Benny WB, Massing BG. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients. Transfusion. 1995 Aug; 35(8):645-52. PMID: 7631404.
    Citations:    Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Jacobson's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (278)
Explore
_
Co-Authors (143)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.